Tharimmune.

Discover historical prices for THAR stock on Yahoo Finance. View daily, weekly or monthly format back to when Tharimmune, Inc. stock was issued.Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) ACCESSWIRE - Mon Nov 27, 2:00AM CST. BRIDGEWATER, NJ / ACCESSWIRE / November 27, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology …The average price predicted for Tharimmune Inc (THAR) by analysts is $4.00, which is $3.79 above the current market price. The public float for THAR is 13.21M, and at present, short sellers hold a 2.71% of that float. On November 17, 2023, the average trading volume of THAR was 1.86M shares.Tharimmune Inc THAR has executed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset, AV104 (to be renamed TH104). TH104 has a ...Tharimmune Inc (THAR) reported Q3 2023 earnings per share (EPS) of -$0.11, missing estimates of -$0.05 by 110.40%. In the same quarter last year, Tharimmune ...

About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.

6 days ago ... Tharimmune (NASDAQ: THAR) is one of those little poster boy stocks to see how the funding of development pharma companies works.Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...

03/16/2023. 12/31/2022. 10-K. Annual Reports. SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. Tharimmune Inc. SEC filings breakout by MarketWatch. View the THAR U.S. Securities and ...Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an …Tharimmune, Inc. 1200 Route 22 East Suite 2000 Bridgewater, NJ 08807 United States 908 955 3140 https://www.tharimmune.com Sector(s) : Healthcare Industry : Biotechnology Full Time Employees : 1

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...

Company Info Tharimmune Inc. 1200 Route 22 East. Suite 2000. Bridgewater New Jersey 08807. United States. Website. Map. Employees 2. Sector Biotechnology.

Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and ...Nov 28, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ... ABOUT US. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in primary biliary cholangitis (PBC ...Tharimmune () stock is rising higher alongside a new licensing agreement. The company is going to handle the development of TH104. This news brings heavy trading to THAR stock on Tuesday.Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron med iated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an …

Tharimmune stock is falling on Tuesday after announcing a public offering. The company priced a 10 million share offering at $1 each. That’s well below its prior closing price and explains why ...Tharimmune (NASDAQ: THAR) stock is taking off on Tuesday after the company underwent a name change. A filing with the Securities and Exchange …Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... In this article. THAR Dropping fast. Tharimmune (NASDAQ: THAR) stock is falling on Tuesday after the clinical-stage biotechnology company announced a public offering for its shares. That public ...Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023 Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …7 days ago ... Tharimmune also announced plans on a development timeline for a Phase 2a study in chronic pruritis in primary biliary cholangitis (PBC) patients ...

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...

Tharimmune Inc. stock performance at a glance Check Tharimmune Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. THAR Stock PerformanceTharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Latest News. Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis November 6, 2023; Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023 Dawson James Securities …Get the latest Tharimmune, Inc. (THAR) stock news and headlines to help you in your trading and investing decisions.Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis November 6, 2023; Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 202317-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...Nov 7, 2023 · Tharimmune () stock is rising higher alongside a new licensing agreement. The company is going to handle the development of TH104. This news brings heavy trading to THAR stock on Tuesday. Nov 6, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... Nov 30, 2023 · About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.

Why Tharimmune Stock (THAR) Is Trading Lower. Tharimmune inc is undergoing a 1-for-25 reverse stock split of its shares. The company's shares are trading lower by 9.7% to $0.19 on monday. The reverse split will take effect on november 20. Tharimmune says the move is to meet nasdaq's minimum bid price requirement.

That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...

Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 9.7% to $0.19 during Monday's session, pulling back following Friday's strength, after the company announced it is undergoing a 1-for-25 ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...View THAR: Tharimmune, Inc.investment & stock information. Get the latest THAR: Tharimmune, Inc. detailed stock quotes, stock data, Real-Time ECN, charts, stats and ...6 days ago ... Tharimmune, Inc. (NASDAQ: THAR) announced the pricing of an underwritten public offering of 10,000,000 shares of common stock sold at $1.00 ...Nov 20, 2023 · Tharimmune stock is falling on plans for a reverse stock split. That split will go into effect after markets close on Monday. The reverse stock split is designed to boost its shares above $1. 13-Jun-2022 ... Each share is being sold to the public at a price of $0.50 for gross proceeds of $2,650,000, before deducting underwriting discounts and ...Hillstream BioPharma Inc. - Tharimmune Announces 1-for-25 Reverse Stock Split - EX-99.1 - November 17, 2023(NASDAQ: THAR) Tharimmune stock price per share is $0.75 today (as of Dec 1, 2023).Tharimmune (NASDAQ: THAR) stock is taking off on Tuesday after the company underwent a name change. A filing with the Securities and Exchange Commission (SEC) reveals that Tharimmune has ...

Tharimmune (NASDAQ:THAR) announced the pricing of an underwritten public offering of 10,000,000 shares of common stock. Each share of common stock is being sold at a public offering price of $1.00 ...That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Nov 27, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... Instagram:https://instagram. best pet insurance in wisconsinlumen tech stocktop rated final expense insurance companiessomnus therapy Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023 Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / … suzie orman booksis humana a good dental insurance Last Revised: June 9, 2023 These terms and conditions of use (the “Terms”) govern your use of our online interfaces and properties (e.g., websites and mobile ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting ... chiropractic care without insurance That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Nov 28, 2023 · Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Shares of SenesTech, Inc. (NASDAQ:SNES) were down 50% to $0.9181 after the company reported pricing of ...